India Merger Acquisition MCA Regulatory Filings — October 13, 2026
Across the 18 filings, the dominant theme is India's corporate restructuring pipeline: scheme-driven amalgamations (Ambuja-ACC, Kedia-Kirti, Aequs fast-track), mandatory open offers and stake buy-ins (Inani Securities, Advent Hotels, GTPL Hathway, Dr. Lal PathLabs/CPL), and subsidiary capital infusions (Info Edge, Jubilant Ingrevia). The most material development is the Aequs Ltd Section 233 scheme returned by the Regional Director on the 90% shareholder-approval shortfall (88.9% voted value), which raises execution and timing risk for an otherwise routine internal restructuring. The Ambuja-ACC NCLT hearing on November 19, 2026 is the largest scheduled catalyst in the set and will be the key date for the combined cement entity. Period-over-period data is mixed: GTPL Hathway grew revenue 16.0% YoY but swung to a loss and more than doubled standalone receivables, while BD&P Hotels turnover growth slowed to 3.9% from roughly 23.8%, and Centrapath Labs turnover fell about 13.5%. Several filings (Hubtown/RTPL turnover of Rs.9,802.79 lakh vs Rs.40.45 lakh prior year, Mehai's nil-revenue target) involve early-stage or non-operating targets, so headline valuations should be read as strategic rather than earnings-based. Most transactions are explicitly arm's length with no promoter or group interest and no regulatory approvals needed, which lowers governance risk but also means limited disclosed deal economics for several entries.